@article{
 title = {Multiparameter optimization in CNS drug discovery: Design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT2C) receptor agonists with exquisite functional selectivity over 5-HT2A and 5-HT2B receptors},
 type = {article},
 year = {2014},
 pages = {5258-5269},
 volume = {57},
 websites = {http://dx.doi.org/10.1021/jm5003292,http://pubs.acs.org/doi/pdfplus/10.1021/jm5003292},
 publisher = {American Chemical Society},
 id = {f65f3968-c2f8-3d4a-92a3-6f4e4f03e959},
 created = {2015-10-01T17:18:09.000Z},
 file_attached = {true},
 profile_id = {64f7fb50-d000-335d-a02d-06c5f340a97a},
 last_modified = {2018-07-09T12:39:50.237Z},
 read = {false},
 starred = {false},
 authored = {true},
 confirmed = {true},
 hidden = {false},
 citation_key = {Storer2014},
 source_type = {Journal Article},
 private_publication = {false},
 abstract = {A series of 4-substituted pyrimido[4,5-d]azepines that are potent, selective 5-HT2C receptor partial agonists is described. A rational medicinal chemistry design strategy to deliver CNS penetration coupled with SAR-based optimization of selectivity and agonist potency provided compounds with the desired balance of preclinical properties. Lead compounds 17 (PF-4479745) and 18 (PF-4522654) displayed robust pharmacology in a preclinical canine model of stress urinary incontinence (SUI) and no measurable functional agonism at the key selectivity targets 5-HT2A and 5-HT2B in relevant tissue-based assay systems. Utilizing recent advances in the structural biology of GPCRs, homology modeling has been carried out to rationalize binding and agonist efficacy of these compounds.},
 bibtype = {article},
 author = {Storer, R. Ian and Brennan, Paul E. and Brown, Alan D. and Bungay, Peter J. and Conlon, Kelly M. and Corbett, Matthew S. and Depianta, Robert P. and Fish, Paul V. and Heifetz, Alexander and Ho, Danny K H and Jessiman, Alan S. and McMurray, Gordon and De Oliveira, Cesar Augusto F and Roberts, Lee R. and Root, James A. and Shanmugasundaram, Veerabahu and Shapiro, Michael J. and Skerten, Melanie and Westbrook, Dominique and Wheeler, Simon and Whitlock, Gavin A. and Wright, John},
 doi = {10.1021/jm5003292},
 journal = {Journal of Medicinal Chemistry},
 number = {12}
}

{"_id":"DKkzSrCCNu6mh6Gm4","bibbaseid":"storer-brennan-brown-bungay-conlon-corbett-depianta-fish-etal-multiparameteroptimizationincnsdrugdiscoverydesignofpyrimido45dazepinesaspotent5hydroxytryptamine2c5ht2creceptoragonistswithexquisitefunctionalselectivityover5ht2aand5ht2breceptors-2014","authorIDs":["g4JkphGbeNea298iY"],"author_short":["Storer, R., I.","Brennan, P., E.","Brown, A., D.","Bungay, P., J.","Conlon, K., M.","Corbett, M., S.","Depianta, R., P.","Fish, P., V.","Heifetz, A.","Ho, D., K., H.","Jessiman, A., S.","McMurray, G.","De Oliveira, C., A., F.","Roberts, L., R.","Root, J., A.","Shanmugasundaram, V.","Shapiro, M., J.","Skerten, M.","Westbrook, D.","Wheeler, S.","Whitlock, G., A.","Wright, J."],"bibdata":{"title":"Multiparameter optimization in CNS drug discovery: Design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT2C) receptor agonists with exquisite functional selectivity over 5-HT2A and 5-HT2B receptors","type":"article","year":"2014","pages":"5258-5269","volume":"57","websites":"http://dx.doi.org/10.1021/jm5003292,http://pubs.acs.org/doi/pdfplus/10.1021/jm5003292","publisher":"American Chemical Society","id":"f65f3968-c2f8-3d4a-92a3-6f4e4f03e959","created":"2015-10-01T17:18:09.000Z","file_attached":"true","profile_id":"64f7fb50-d000-335d-a02d-06c5f340a97a","last_modified":"2018-07-09T12:39:50.237Z","read":false,"starred":false,"authored":"true","confirmed":"true","hidden":false,"citation_key":"Storer2014","source_type":"Journal Article","private_publication":false,"abstract":"A series of 4-substituted pyrimido[4,5-d]azepines that are potent, selective 5-HT2C receptor partial agonists is described. A rational medicinal chemistry design strategy to deliver CNS penetration coupled with SAR-based optimization of selectivity and agonist potency provided compounds with the desired balance of preclinical properties. Lead compounds 17 (PF-4479745) and 18 (PF-4522654) displayed robust pharmacology in a preclinical canine model of stress urinary incontinence (SUI) and no measurable functional agonism at the key selectivity targets 5-HT2A and 5-HT2B in relevant tissue-based assay systems. Utilizing recent advances in the structural biology of GPCRs, homology modeling has been carried out to rationalize binding and agonist efficacy of these compounds.","bibtype":"article","author":"Storer, R. Ian and Brennan, Paul E. and Brown, Alan D. and Bungay, Peter J. and Conlon, Kelly M. and Corbett, Matthew S. and Depianta, Robert P. and Fish, Paul V. and Heifetz, Alexander and Ho, Danny K H and Jessiman, Alan S. and McMurray, Gordon and De Oliveira, Cesar Augusto F and Roberts, Lee R. and Root, James A. and Shanmugasundaram, Veerabahu and Shapiro, Michael J. and Skerten, Melanie and Westbrook, Dominique and Wheeler, Simon and Whitlock, Gavin A. and Wright, John","doi":"10.1021/jm5003292","journal":"Journal of Medicinal Chemistry","number":"12","bibtex":"@article{\n title = {Multiparameter optimization in CNS drug discovery: Design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT2C) receptor agonists with exquisite functional selectivity over 5-HT2A and 5-HT2B receptors},\n type = {article},\n year = {2014},\n pages = {5258-5269},\n volume = {57},\n websites = {http://dx.doi.org/10.1021/jm5003292,http://pubs.acs.org/doi/pdfplus/10.1021/jm5003292},\n publisher = {American Chemical Society},\n id = {f65f3968-c2f8-3d4a-92a3-6f4e4f03e959},\n created = {2015-10-01T17:18:09.000Z},\n file_attached = {true},\n profile_id = {64f7fb50-d000-335d-a02d-06c5f340a97a},\n last_modified = {2018-07-09T12:39:50.237Z},\n read = {false},\n starred = {false},\n authored = {true},\n confirmed = {true},\n hidden = {false},\n citation_key = {Storer2014},\n source_type = {Journal Article},\n private_publication = {false},\n abstract = {A series of 4-substituted pyrimido[4,5-d]azepines that are potent, selective 5-HT2C receptor partial agonists is described. A rational medicinal chemistry design strategy to deliver CNS penetration coupled with SAR-based optimization of selectivity and agonist potency provided compounds with the desired balance of preclinical properties. Lead compounds 17 (PF-4479745) and 18 (PF-4522654) displayed robust pharmacology in a preclinical canine model of stress urinary incontinence (SUI) and no measurable functional agonism at the key selectivity targets 5-HT2A and 5-HT2B in relevant tissue-based assay systems. Utilizing recent advances in the structural biology of GPCRs, homology modeling has been carried out to rationalize binding and agonist efficacy of these compounds.},\n bibtype = {article},\n author = {Storer, R. Ian and Brennan, Paul E. and Brown, Alan D. and Bungay, Peter J. and Conlon, Kelly M. and Corbett, Matthew S. and Depianta, Robert P. and Fish, Paul V. and Heifetz, Alexander and Ho, Danny K H and Jessiman, Alan S. and McMurray, Gordon and De Oliveira, Cesar Augusto F and Roberts, Lee R. and Root, James A. and Shanmugasundaram, Veerabahu and Shapiro, Michael J. and Skerten, Melanie and Westbrook, Dominique and Wheeler, Simon and Whitlock, Gavin A. and Wright, John},\n doi = {10.1021/jm5003292},\n journal = {Journal of Medicinal Chemistry},\n number = {12}\n}","author_short":["Storer, R., I.","Brennan, P., E.","Brown, A., D.","Bungay, P., J.","Conlon, K., M.","Corbett, M., S.","Depianta, R., P.","Fish, P., V.","Heifetz, A.","Ho, D., K., H.","Jessiman, A., S.","McMurray, G.","De Oliveira, C., A., F.","Roberts, L., R.","Root, J., A.","Shanmugasundaram, V.","Shapiro, M., J.","Skerten, M.","Westbrook, D.","Wheeler, S.","Whitlock, G., A.","Wright, J."],"urls":{"Paper":"https://bibbase.org/service/mendeley/64f7fb50-d000-335d-a02d-06c5f340a97a/file/15dbfff3-92f1-4687-59af-8e9d6d6b3dd9/2014-Multiparameter_optimization_in_CNS_drug_discovery_Design_of_pyrimido45-dazepines_as_potent_5-hydroxytryptamine_2C_(.pdf.pdf","Website":"http://dx.doi.org/10.1021/jm5003292,http://pubs.acs.org/doi/pdfplus/10.1021/jm5003292"},"biburl":"https://bibbase.org/service/mendeley/64f7fb50-d000-335d-a02d-06c5f340a97a","bibbaseid":"storer-brennan-brown-bungay-conlon-corbett-depianta-fish-etal-multiparameteroptimizationincnsdrugdiscoverydesignofpyrimido45dazepinesaspotent5hydroxytryptamine2c5ht2creceptoragonistswithexquisitefunctionalselectivityover5ht2aand5ht2breceptors-2014","role":"author","metadata":{"authorlinks":{"brennan, p":"https://www.brennanresearchgroup.com/publications"}},"downloads":0},"bibtype":"article","creationDate":"2020-12-14T11:34:08.265Z","downloads":0,"keywords":[],"search_terms":["multiparameter","optimization","cns","drug","discovery","design","pyrimido","azepines","potent","hydroxytryptamine","ht2c","receptor","agonists","exquisite","functional","selectivity","over","ht2a","ht2b","receptors","storer","brennan","brown","bungay","conlon","corbett","depianta","fish","heifetz","ho","jessiman","mcmurray","de oliveira","roberts","root","shanmugasundaram","shapiro","skerten","westbrook","wheeler","whitlock","wright"],"title":"Multiparameter optimization in CNS drug discovery: Design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT2C) receptor agonists with exquisite functional selectivity over 5-HT2A and 5-HT2B receptors","year":2014,"biburl":"https://bibbase.org/service/mendeley/64f7fb50-d000-335d-a02d-06c5f340a97a","dataSources":["Pa586au6MYhHM9r97","ya2CyA73rpZseyrZ8","2252seNhipfTmjEBQ"]}